• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

比较腹膜转移灶和卵巢肿瘤组织中肿瘤浸润淋巴细胞上 PD-1 和 PD-L1 的表达及其与临床结局的关系。

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.

机构信息

Department of Obstetrics and Gynecology, Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.

Division of General Surgery, Department of Surgery, Comprehensive Cancer Center (CCC), Medical University of Vienna, Vienna, Austria.

出版信息

Sci Rep. 2021 Mar 18;11(1):6400. doi: 10.1038/s41598-021-85966-0.

DOI:10.1038/s41598-021-85966-0
PMID:33737722
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7973418/
Abstract

The therapeutic potential of immune checkpoint inhibitors is currently being investigated in epithelial ovarian cancer (EOC), but immunological effects of the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) axis in EOC still remain poorly understood. The aim of this study was thus to compare infiltration rates of PD-1 and PD-L1 expressing tumor infiltrating leucocytes (TILs) in primary ovarian tumor tissue and metastatic intraperitoneal implants and to investigate its impact on overall survival (OS). Tumor specimens (ovarian tumor tissues and intraperitoneal metastases) of 111 patients were used to investigate the PD-1, PD-L1 and CD8 expression rates on TILs and PD-L1 expression rate of tumor cells. The percentages of CD8, PD-1, and PD-L1 expressing subpopulations of TILs differ in primary ovarian tumor tissues and metastatic intraperitoneal implants. High PD-1 among TILs in peritoneal metastases were associated with favorable OS. High PD-L1 expression in TILs was associated with poor OS. Combining both factors in peritoneal metastases revealed an unfavorable prognosis. Primary ovarian tumor tissue and intraperitoneal metastatic tissues in EOC might have different strategies to evade immune control. Those findings are of importance for the process of biomarker assessment to predict patients' response to immunotherapy.

摘要

免疫检查点抑制剂在卵巢上皮癌(EOC)中的治疗潜力正在研究中,但 PD-1/PD-L1 轴在 EOC 中的免疫作用仍知之甚少。因此,本研究旨在比较原发性卵巢肿瘤组织和转移性腹膜内种植体中 PD-1 和 PD-L1 表达的肿瘤浸润性白细胞(TIL)的浸润率,并研究其对总生存期(OS)的影响。使用 111 例患者的肿瘤标本(卵巢肿瘤组织和腹膜内转移)来研究 TIL 上的 PD-1、PD-L1 和 CD8 表达率以及肿瘤细胞上的 PD-L1 表达率。TIL 中 CD8、PD-1 和 PD-L1 表达亚群的百分比在原发性卵巢肿瘤组织和转移性腹膜内种植体中有所不同。腹膜转移中 TIL 中的高 PD-1 与良好的 OS 相关。TIL 中的高 PD-L1 表达与较差的 OS 相关。在腹膜转移中同时考虑这两个因素显示出不利的预后。EOC 中的原发性卵巢肿瘤组织和腹膜内转移组织可能有不同的策略来逃避免疫控制。这些发现对于生物标志物评估过程以预测患者对免疫治疗的反应具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34d1/7973418/9d45e02e81aa/41598_2021_85966_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34d1/7973418/ba46e3295591/41598_2021_85966_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34d1/7973418/676a73b73e4b/41598_2021_85966_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34d1/7973418/9d45e02e81aa/41598_2021_85966_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34d1/7973418/ba46e3295591/41598_2021_85966_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34d1/7973418/676a73b73e4b/41598_2021_85966_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/34d1/7973418/9d45e02e81aa/41598_2021_85966_Fig3_HTML.jpg

相似文献

1
PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome.比较腹膜转移灶和卵巢肿瘤组织中肿瘤浸润淋巴细胞上 PD-1 和 PD-L1 的表达及其与临床结局的关系。
Sci Rep. 2021 Mar 18;11(1):6400. doi: 10.1038/s41598-021-85966-0.
2
Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).新辅助化疗(NACT)增加上皮性卵巢癌(EOC)中的免疫浸润和程序性死亡配体 1(PD-L1)表达。
Ann Oncol. 2017 Mar 1;28(3):651-657. doi: 10.1093/annonc/mdw625.
3
Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC).程序性死亡配体-1和CD8肿瘤浸润淋巴细胞(TILs)作为高级别浆液性卵巢癌(HGSC)的预后预测指标
J Egypt Natl Canc Inst. 2021 Jul 9;33(1):16. doi: 10.1186/s43046-021-00073-5.
4
Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.程序性细胞死亡蛋白-1(PD-1)和PD-配体1(PD-L1)在卵巢高级别浆液性癌的癌细胞及肿瘤浸润淋巴细胞中的表达对预后的影响
Oncotarget. 2016 Jan 12;7(2):1486-99. doi: 10.18632/oncotarget.6429.
5
Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.卵巢癌中程序性细胞死亡受体 1(PD-1)和程序性死亡配体 1(PD-L1)表达的卵巢肿瘤病理学分层。
J Ovarian Res. 2018 May 30;11(1):43. doi: 10.1186/s13048-018-0414-z.
6
Significance of evaluating tumor-infiltrating lymphocytes (TILs) and programmed cell death-ligand 1 (PD-L1) expression in breast cancer.评估乳腺癌中肿瘤浸润淋巴细胞(TILs)和程序性细胞死亡配体1(PD-L1)表达的意义。
Med Mol Morphol. 2017 Dec;50(4):185-194. doi: 10.1007/s00795-017-0170-y. Epub 2017 Sep 21.
7
Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.程序性死亡受体 1/程序性死亡配体 1 通路在胃神经内分泌癌中的临床意义。
World J Gastroenterol. 2019 Apr 14;25(14):1684-1696. doi: 10.3748/wjg.v25.i14.1684.
8
Programmed cell death ligand-1 (PD-L1) expression combined with CD8 tumor infiltrating lymphocytes density in non-small cell lung cancer patients.非小细胞肺癌患者中程序性细胞死亡配体-1(PD-L1)表达与CD8肿瘤浸润淋巴细胞密度的联合情况
J Egypt Natl Canc Inst. 2018 Dec;30(4):125-131. doi: 10.1016/j.jnci.2018.08.003. Epub 2018 Oct 15.
9
PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.PD-L1 在卵巢癌中高度表达,与表达 CD44 和其他干细胞标志物的癌症干细胞群体相关。
BMC Cancer. 2023 Jan 5;23(1):13. doi: 10.1186/s12885-022-10404-x.
10
Prognostic value of tumor PD-L1 expression combined with CD8 tumor infiltrating lymphocytes in high grade serous ovarian cancer.肿瘤 PD-L1 表达联合 CD8 肿瘤浸润淋巴细胞对高级别浆液性卵巢癌的预后价值。
Int Immunopharmacol. 2017 Nov;52:7-14. doi: 10.1016/j.intimp.2017.08.017. Epub 2017 Aug 31.

引用本文的文献

1
Association of Tumor-Infiltrating Lymphocytes and Inflammation Status with Survival Outcome in Patients with High-Grade Serous Ovarian Carcinoma.高级别浆液性卵巢癌患者肿瘤浸润淋巴细胞及炎症状态与生存结局的相关性
Cancers (Basel). 2025 Jul 8;17(14):2269. doi: 10.3390/cancers17142269.
2
PD-1 involvement in CD8+ tumor-infiltrating lymphocytes in patients with colonic-derived peritoneal adenocarcinoma.程序性死亡受体1(PD-1)在结肠源性腹膜腺癌患者的CD8 +肿瘤浸润淋巴细胞中的作用。
Braz J Med Biol Res. 2025 Apr 14;58:e14467. doi: 10.1590/1414-431X2025e14467. eCollection 2025.
3
Inflammation and Immune Escape in Ovarian Cancer: Pathways and Therapeutic Opportunities.

本文引用的文献

1
PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer.PD-L1 与 T 细胞的结合促进了自身耐受性,并抑制了癌症中相邻的巨噬细胞和效应 T 细胞。
Nat Immunol. 2020 Apr;21(4):442-454. doi: 10.1038/s41590-020-0620-x. Epub 2020 Mar 9.
2
Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer.精准医学肿瘤多学科讨论会议:个性化治疗理念在卵巢癌中的临床适用性
Cancers (Basel). 2020 Feb 27;12(3):548. doi: 10.3390/cancers12030548.
3
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.
卵巢癌中的炎症与免疫逃逸:途径与治疗机遇
J Inflamm Res. 2025 Jan 21;18:895-909. doi: 10.2147/JIR.S503479. eCollection 2025.
4
Quantifying intratumoral biomarker heterogeneity in tubo-ovarian high-grade serous carcinoma to optimize clinical translation.量化输卵管卵巢高级别浆液性癌中的肿瘤内生物标志物异质性以优化临床转化。
Sci Rep. 2025 Jan 20;15(1):2459. doi: 10.1038/s41598-024-82206-z.
5
Expression and clinical significance of PD-L1 and infiltrated immune cells in the gastric adenocarcinoma microenvironment.胃腺癌微环境中 PD-L1 和浸润免疫细胞的表达及临床意义。
Medicine (Baltimore). 2023 Dec 1;102(48):e36323. doi: 10.1097/MD.0000000000036323.
6
Peripheral PD-1 and Tim-3 percentages are associated with primary sites and pathological types of peritoneal neoplasms.外周血 PD-1 和 Tim-3 比例与腹膜肿瘤的原发部位和病理类型相关。
BMC Cancer. 2023 Mar 29;23(1):287. doi: 10.1186/s12885-023-10752-2.
7
Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints.上皮性卵巢癌中的肿瘤浸润淋巴细胞(TILs):异质性、预后影响及与免疫检查点的关系
Cancers (Basel). 2022 Oct 29;14(21):5332. doi: 10.3390/cancers14215332.
8
Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy.非经典 PD-1/PD-L1 轴与抗 PD 治疗疗效的关系。
Front Immunol. 2022 May 18;13:910704. doi: 10.3389/fimmu.2022.910704. eCollection 2022.
9
Biomarkers expression among paired serous ovarian cancer primary lesions and their peritoneal cavity metastases in treatment-naïve patients: A single-center study.治疗初治患者中配对浆液性卵巢癌原发灶及其腹腔转移灶的生物标志物表达:一项单中心研究。
Cancer Med. 2022 Jun;11(11):2193-2203. doi: 10.1002/cam4.4600. Epub 2022 Feb 25.
10
PD-L1 Expression in Different Segments and Histological Types of Ovarian Cancer According to Lymphocytic Infiltrate.根据淋巴细胞浸润情况分析卵巢癌不同节段和组织学类型的 PD-L1 表达
Medicina (Kaunas). 2021 Nov 29;57(12):1309. doi: 10.3390/medicina57121309.
PD-1/PD-L1 表达和肿瘤浸润淋巴细胞在晚期高级别浆液性卵巢癌中具有预后意义。
Virchows Arch. 2020 Jul;477(1):83-91. doi: 10.1007/s00428-020-02751-6. Epub 2020 Jan 24.
4
Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study.基于基因表达的计算研究:高级别浆液性卵巢癌亚型中铂类化疗后肿瘤免疫细胞浸润和存活。
EBioMedicine. 2020 Jan;51:102602. doi: 10.1016/j.ebiom.2019.102602. Epub 2020 Jan 3.
5
Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer.原发性卵巢癌中原发肿瘤与相应转移灶之间的免疫异质性及对铂类治疗的反应
Cancers (Basel). 2019 Aug 26;11(9):1250. doi: 10.3390/cancers11091250.
6
PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma.肿瘤浸润性淋巴细胞中 PD-L1 的表达是卵巢浆液性癌的一个有利预后因素。
J Ovarian Res. 2019 Jun 17;12(1):56. doi: 10.1186/s13048-019-0526-0.
7
Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study.帕博利珠单抗治疗晚期复发性卵巢癌患者的抗肿瘤活性和安全性:来自 II 期 KEYNOTE-100 研究的结果。
Ann Oncol. 2019 Jul 1;30(7):1080-1087. doi: 10.1093/annonc/mdz135.
8
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.阿维鲁单抗治疗复发性或难治性卵巢癌患者的疗效和安全性:JAVELIN 实体瘤试验的 1b 期结果。
JAMA Oncol. 2019 Mar 1;5(3):393-401. doi: 10.1001/jamaoncol.2018.6258.
9
Clinical significance of the immune microenvironment in ovarian cancer patients.卵巢癌患者免疫微环境的临床意义。
Mol Omics. 2018 Oct 8;14(5):341-351. doi: 10.1039/c8mo00128f.
10
T Cell Dysfunction in Cancer.肿瘤中的 T 细胞功能障碍。
Cancer Cell. 2018 Apr 9;33(4):547-562. doi: 10.1016/j.ccell.2018.03.012.